Long-term retention rate of mepolizumab treatment in severe asthma: a 36-months real-life experience-Reference-Cited by-同舟云学术

Long-term retention rate of mepolizumab treatment in severe asthma: a 36-months real-life experience

Published:2022-02-12 Issue:1 Volume:60 Page:158-166
ISSN:0277-0903
Container-title:Journal of Asthma
language:en
Short-container-title:Journal of Asthma

Author:

Matucci Andrea¹^ORCID,Vivarelli Emanuele¹,Bormioli Susanna²,Francesca Nencini¹,Chiccoli Fabio³,Valentina Mecheri³,Francesca Grosso³,Oliviero Rossi¹,Parronchi Paola³,Vultaggio Alessandra¹

Affiliation:

1. Immunoallergology Unit, Careggi University Hospital, Florence, Italy

2. Allergology and Clinical Immunology Unit, San Giovanni Di Dio Hospital, Florence, Italy

3. Department of Clinical and Experimental Medicine, Unit of Internal Medicine, University of Florence, Florence, Italy

Publisher

Informa UK Limited

Subject

Pulmonary and Respiratory Medicine,Immunology and Allergy,Pediatrics, Perinatology and Child Health

Link

https://www.tandfonline.com/doi/pdf/10.1080/02770903.2022.2036754

Reference41 articles.

1. Global Initiative for Asthma. Global strategy for asthma management and prevention; 2020. [accessed 2020 Sep 30]. https://ginasthma.org.

2. High prevalence of severe asthma in a large random population study

3. GINA. Difficult to treat & severe asthma in adolescent and adult patients. Diagnosis and management; 2019. https://ginasthma.org.

4. A retrospective cohort study evaluating healthcare resource utilization in patients with asthma in Japan

5. Severe and Difficult-to-Treat Asthma in Adults

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Titration of anti-IL-5 biologics in severe asthma: an open-label randomised controlled trial (the OPTIMAL study);European Respiratory Journal;2024-06-06

2. Factors associated with drug retention of mepolizumab in patients with eosinophilic granulomatosis with polyangiitis: A multicentre REVEAL cohort study;Modern Rheumatology;2024-05-10

3. Evaluation of Clinical Remission in Best-Performing Severe Asthmatic Patients Treated for Three Years with Mepolizumab;Biomedicines;2024-04-26

4. Long-Term Clinical and Sustained REMIssion in Severe Eosinophilic Asthma treated with Mepolizumab: The REMI-M study;2024-03-15

5. Mepolizumab in children and adolescents with severe eosinophilic asthma not eligible for omalizumab: a single Center experience;Journal of Asthma;2024-01-24